30.14

3.34% -1.04

After Hours: 30.14

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $30.14, with a volume of 1.34M. It is down -3.34% in the last 24 hours and down -5.99% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$31.18

Open:

$30.63

24h Volume:

1.34M

Relative Volume:

1.62

Market Cap:

$3.47B

Revenue:

$14.09M

Net Income/Loss:

$-176.94M

P/E Ratio:

-14.02

EPS:

-2.15

Net Cash Flow:

$-141.24M

1W Performance:

-12.08%

1M Performance:

-5.99%

6M Performance:

+11.63%

1Y Performance:

+30.93%

1-Day Range:

$29.65

$30.63

1-Week Range:

$29.65

$35.71

52-Week Range:

$14.06

$42.00

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	30.14	3.58B	14.09M	-176.94M	-141.24M	-2.15
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.11	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Mar 04, 2026

NewAmsterdam Pharma Hits Day Low at $30.20 Amid Price Pressure - Markets Mojo

Mar 04, 2026

Mar 03, 2026

NewAmsterdam Pharma (NAMS) Stock Analysis: Exploring a 46.68% Potential Upside Amidst Strong Buy Ratings - DirectorsTalk Interviews

Mar 03, 2026

Mar 02, 2026

NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $14,753,257.75 in Stock - MarketBeat

Mar 02, 2026

NewAmsterdam Pharma CEO Sells Over $14 Million in Shares - TradingView

Mar 02, 2026

NewAmsterdam Pharma (NAMS) CEO sells 443,707 shares after option exercise - Stock Titan

Mar 02, 2026

NewAmsterdam Pharma (NASDAQ: NAMS) files Form 144 to sell 443,707 shares - Stock Titan

Mar 02, 2026

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Large Volume IncreaseStill a Buy? - MarketBeat

Mar 02, 2026

NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation - TipRanks

Mar 02, 2026

NewAmsterdam posts updated investor presentation highlighting obicetrapib efficacy, safety, IP and cash runway - TradingView

Mar 02, 2026

Obicetrapib data and AD signals in NewAmsterdam (NAMS) deck - Stock Titan

Mar 02, 2026

Handelsbanken Fonder AB Boosts Stake in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Mar 02, 2026

Feb 28, 2026

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March - Sahm

Feb 28, 2026

JPMorgan Chase & Co. Has $37.04 Million Position in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Feb 28, 2026

Feb 26, 2026

Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells 58,253 Shares of Stock - MarketBeat

Feb 26, 2026

NewAmsterdam Pharma (NAMS) CEO exercises options and sells 306,293 shares - Stock Titan

Feb 26, 2026

Liquidity Mapping Around (NAMS) Price Events - Stock Traders Daily

Feb 26, 2026

Feb 25, 2026

Rate Hike: Is NewAmsterdam Pharma Company NV stock overvalued or fairly pricedJuly 2025 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Feb 25, 2026

Heart drug developer NewAmsterdam opens March investor webcasts - Stock Titan

Feb 25, 2026

NAMS Stock Price and Chart — NASDAQ:NAMS - TradingView

Feb 25, 2026

NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Play with 34.71% Upside Potential - DirectorsTalk Interviews

Feb 25, 2026

Feb 24, 2026

Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock - MarketBeat

Feb 24, 2026

The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following Obicetrapib-Focused 2025 Results And Share Shelf Filing - simplywall.st

Feb 24, 2026

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Feb 24, 2026

Feb 23, 2026

NAMS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Feb 23, 2026

Q1 Earnings Forecast for NAMS Issued By HC Wainwright - MarketBeat

Feb 23, 2026

Feb 21, 2026

Published on: 2026-02-22 03:05:00 - baoquankhu1.vn

Feb 21, 2026

Feb 20, 2026

Can NewAmsterdam Pharma Company N.V. Equity Warrant stock beat analyst upgradesGap Up & Reliable Volume Spike Alerts - mfd.ru

Feb 20, 2026

What is HC Wainwright's Estimate for NAMS Q3 Earnings? - MarketBeat

Feb 20, 2026

6,000‑Share Rule 144 Sale by NewAmsterdam Pharma (NASDAQ: NAMS) - Stock Titan

Feb 20, 2026

Cantor Fitzgerald Maintains Overweight on NAMS NewAmsterdam Pharma Feb 2026 - Meyka

Feb 20, 2026

Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight - Investing.com Nigeria

Feb 20, 2026

Guggenheim raises NewAmsterdam Pharma stock price target on EU launch timing - Investing.com Nigeria

Feb 20, 2026

Feb 19, 2026

Cantor Fitzgerald reiterates NewAmsterdam Pharma stock rating at Overweight By Investing.com - Investing.com Australia

Feb 19, 2026

Readystate Asset Management LP Sells 196,841 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Feb 19, 2026

Ideas Watch: What are NewAmsterdam Pharma Company NVs technical support levels2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn

Feb 19, 2026

Aberdeen Group plc Has $18.83 Million Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat

Feb 19, 2026

Needham & Company LLC Issues Positive Forecast for NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price - Defense World

Feb 19, 2026

Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insi - GuruFocus

Feb 19, 2026

Feb 18, 2026

Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co - Benzinga

Feb 18, 2026

Earnings Summary: NewAmsterdam Pharma Co Q4 - Benzinga

Feb 18, 2026

NewAmsterdam Pharma Narrows Net Loss in 2025, Revenue Drops - marketscreener.com

Feb 18, 2026

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update - The Manila Times

Feb 18, 2026

NewAmsterdam Pharma Co N.V. SEC 10-K Report - TradingView

Feb 18, 2026

Earnings Flash (NAMS) NewAmsterdam Pharma Posts FY 2025 Revenue $22.5M versus $45.6M a Year Ago - marketscreener.com

Feb 18, 2026

Feb 17, 2026

NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 41% Upside Beckons Investors Despite Current Challenges - DirectorsTalk Interviews

Feb 17, 2026

Published on: 2026-02-17 13:42:01 - mfd.ru

Feb 17, 2026

Viking Global discloses 3.7% NewAmsterdam Pharma (NAMS) holding in 13G/A - Stock Titan

Feb 17, 2026

Feb 16, 2026